Phase 1Completed
Bioequivalence Study of Two Products of Tenofovir Alafenamide 25 mg Film Tablet in Healthy, Adult, Human Subjects
An Open Label, Balanced, Randomized, Two-sequence, Two-treatment, Four -Period, Single Oral Dose, Fully Replicate,Bioequivalence Study in Normal, Healthy, Adult, Human Subjects Under Fed Condition.
- Sponsor
- Humanis Saglık Anonim Sirketi (Industry)
- Enrollment
- 42 enrolled
- Conditions
- Chronic Hepatitis B in Adults and Paediatric Patients
- Interventions
- Tenofovir Alafenamide Film coated Tablet; Vemlidy® film-coated tablets
- Ages
- adults
- Registry
- NCT06592300
Full record on ClinicalTrials.gov
From the registry
To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose, fully replicate, bioequivalence study in normal, healthy, adult, human subjects under fed condition.
Primary outcomes
- Maximum plasma concentration (Cmax)
- AArea under the plasma concentration curve from administration to last observed concentration at time t (AUC0-t)
History
Last registry update
Registered
Study completion
Primary completion
Started